Bipolar Disorder, Depressive Disorder, Major, Psychotic Disorders
Conditions
Keywords
Attenuated Psychotic Symptoms
Brief summary
The primary study aims are to determine the clinical, behavioural and social predictors of SMI development in youth, and to investigate whether neuroimaging can distinguish youth who will develop SMI from those who will not. The study's secondary aims are to examine the proportions of the cohort that make transitions between the different clinical stages of risk, and to determine the proportions that have poor outcomes, defined as ongoing or increased symptoms, secondary substance misuse, poor social or role functioning, i.e., non-participation in education, or employment, and new self-harm. Investigators will study a cohort of 240 youth (aged 14-25, male and female) that includes youth with early mood symptoms or sub-threshold psychotic symptoms (symptomatic group; n=160), youth at risk due to a family history of a SMI (family high risk (FHR); n=40), and healthy controls (HC; n=40). From this cohort, clinical, social and cognitive data, as well as imaging data will be gathered to create a multi-layered snapshot of these individuals and provide full-level characterization. Investigators will use the full range of clinical and imaging data generated from this cohort to develop novel prediction algorithms incorporating key variables that predict the development of SMI.
Interventions
None listed
Sponsors
Brain Canada
Sunnybrook Health Sciences Centre
University of Calgary
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
12 Years to 25 Years
Healthy volunteers
Yes
Inclusion criteria
* Participants will understand and sign an informed consent (or assent for minors) document in English.
Exclusion criteria
* meet criteria for current or lifetime Axis I bipolar or psychotic disorder (other Axis I disorders will not be exclusionary as they may be precursors to mood or psychotic disorders); * IQ \< 70; * past or current history of a significant central nervous system disorder or serious medical disorder; and * current pharmacological treatment that would be considered as an adequate trial of treatment for a SMI.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Diagnosis of serious mental illness (SMI) | 2 year | The Structured Clinical Interview for DSM-IV Disorders (SCID-1) will be used to determine the presence of any Axis I disorder |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Level of risk on a Clinical Staging Model for Mental Health Disorders based on the Calgary Depression Scale for Schizophrenia (CDSS). | 2 year | Level of risk will be defined based on a Clinical Staging Model for Mental Health Disorders (Hickie IB, Scott EM, Hermens DF et al. Applying clinical staging to young people who present for mental health care. Early Interv Psychiatry 2012.) Individuals will be assigned a stage based on scores on the CDSS. |
| Level of risk on a Clinical Staging Model for Mental Health Disorders based on the Young Mania Scale | 2 year | Level of risk will be defined based on a Clinical Staging Model for Mental Health Disorders (Hickie IB, Scott EM, Hermens DF et al. Applying clinical staging to young people who present for mental health care. Early Interv Psychiatry 2012.) Individuals will be assigned a stage based on their scores on the Young Mania Scale. |
| Clinical symptoms on the Young Mania Scale. | 2 year | Individuals' clinical symptoms will be measured using scores on the Young Mania Scale. |
| Clinical symptoms on the SOPS. | 2 year | Individuals' clinical symptoms will be measured using scores on positive symptoms on the SOPS. |
| Clinical symptoms on the CDSS. | 2 year | Individuals' clinical symptoms of depression will be measured using scores on the CDSS. |
| Level of risk on a Clinical Staging Model for Mental Health Disorders based on the Scale of Prodromal Symptoms (SOPS) | 2 year | Level of risk will be defined based on a Clinical Staging Model for Mental Health Disorders (Hickie IB, Scott EM, Hermens DF et al. Applying clinical staging to young people who present for mental health care. Early Interv Psychiatry 2012.) Individuals will be assigned a stage based on their scores on the SOPS. |
| Structural brain changes | 2 year | MRI images will be examined for changes in structural data using regional grey matter intensity. |
| Structural Brain changes | 2 year | MRI images will be examined for changes in structural data using white matter integrity |
| Functional Brain changes | 2 year | MRI images will be examined for changes in functional data using resting-state connectivity among brain regions of interest |
| Changes in cognition | 2 year | Cognition is assessed using the MATRICS Cognitive Battery |
| Functioning | 2 year | Functioning will be assessed using Global Functioning (Social & Role) |
Countries
Canada
Outcome results
None listed